Results

1–10 of 30 results for anti-VEGF injections

Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
Progression to Pars Plana Vitrectomy After Monotherapy With Panretinal Photocoagulation or Anti-VEGF injections in Proliferative Diabetic Retinopathy
Karen M Wai, MD
Annual Meeting Talks
2023
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity
Nimesh A. Patel, MD
Annual Meeting Talks
2022
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
A 10-Year Follow-up on Outcomes of Intravitreal Anti-VEGF Injections for Choroidal Neovascularization Secondary to Ocular Histoplasmosis
Carl Noble, DO, MBA
Annual Meeting Talks
2021
The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During the COVID-19 Pandemic
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2021
Comparing Rates of Vitrectomy in Proliferative Diabetic Retinopathy Patients Treated With Anti-VEGF or Panretinal Photocoagulation Monotherapy
Nadim M Rayess, MD
Annual Meeting Talks
2021